Advertisement
U.S. markets open in 6 hours 20 minutes

AstraZeneca PLC (AZN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
65.85-0.46 (-0.69%)
At close: 04:00PM EDT
66.41 +0.56 (+0.86%)
After hours: 07:49PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close66.31
Open66.04
Bid67.66 x 900
Ask67.67 x 1000
Day's Range65.81 - 66.37
52 Week Range60.47 - 76.56
Volume3,568,772
Avg. Volume6,287,378
Market Cap204.162B
Beta (5Y Monthly)0.17
PE Ratio (TTM)34.66
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.45 (2.20%)
Ex-Dividend DateFeb 22, 2024
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
9% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for AZN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Astrazeneca PLC
    Analyst Report: AstraZeneca PLCAstraZeneca is a British-Swedish company with its main headquarters in the U.K. and regional headquarters in Sweden and the U.S. It focuses on treatments for respiratory, autoimmune, and metabolic conditions, as well as on cardiology, neurology, and oncology drugs.
    Rating
    Fair Value
    Economic Moat
    26 days agoArgus Research
View more
  • The Wall Street Journal

    Now That Two Inhaler Makers Are Capping Patient Costs, Will More Follow?

    AstraZeneca’s move on Monday to cap at $35 the out-of-pocket costs that patients pay for the company’s Symbicort inhaler speaks to the political and regulatory pressure coming to bear on manufacturers of certain commonly used but expensive treatments. The British drugmaker’s shift follows a similar step last month by Boehringer Ingelheim, which sells rival inhalers including Atrovent and Spiriva. Sen. Bernie Sanders, the independent from Vermont, launched an investigation of inhaler prices in January.

  • Zacks

    AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It

    Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

  • Reuters

    AstraZeneca to cap out-of-pocket inhaler costs in US, following rival Boehringer's move

    High drug prices in the United States have been the subject of growing political scrutiny for years. Senator Bernie Sanders and other lawmakers in January criticized the top four manufacturers of inhalers sold in the U.S. — AstraZeneca, Boehringer, Teva Pharmaceuticals and GSK — over high prices.